Sorafenib has yet to be FDA approved for treatment of AML, though it has been studied in ND AML, with or without FLT-3 mutations, in combination with intensive chemotherapy in the phase 2 double blind, placebo-controlled SORAML trial. This evidence concerns the gene FLT3 and acute myeloid leukemia.